scholarly journals Advancement on Sustained Antiviral Ocular Drug Delivery for Herpes Simplex Virus Keratitis: Recent Update on Potential Investigation

Pharmaceutics ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 1
Author(s):  
Manisha Pandey ◽  
Hira Choudhury ◽  
Azila Abdul-Aziz ◽  
Subrat Kumar Bhattamisra ◽  
Bapi Gorain ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Herpes Simplex ◽  
Drug Delivery Systems ◽  
Adult Population ◽  
Delivery Systems ◽  
Application Site ◽  
Special Focus ◽  
Herpes Simplex Viruses ◽  
Novel Drug

The eyes are the window to the world and the key to communication, but they are vulnerable to multitudes of ailments. More serious than is thought, corneal infection by herpes simplex viruses (HSVs) is a prevalent yet silent cause of blindness in both the paediatric and adult population, especially if immunodeficient. Globally, there are 1.5 million new cases and forty thousand visual impairment cases reported yearly. The Herpetic Eye Disease Study recommends topical antiviral as the front-line therapy for HSV keratitis. Ironically, topical eye solutions undergo rapid nasolacrimal clearance, which necessitates oral drugs but there is a catch of systemic toxicity. The hurdle of antiviral penetration to reach an effective concentration is further complicated by drugs’ poor permeability and complex layers of ocular barriers. In this current review, novel delivery approaches for ocular herpetic infection, including nanocarriers, prodrugs, and peptides are widely investigated, with special focus on advantages, challenges, and recent updates on in situ gelling systems of ocular HSV infections. In general congruence, the novel drug delivery systems play a vital role in prolonging the ocular drug residence time to achieve controlled release of therapeutic agents at the application site, thus allowing superior ocular bioavailability yet fewer systemic side effects. Moreover, in situ gel functions synergistically with nanocarriers, prodrugs, and peptides. The findings support that novel drug delivery systems have potential in ophthalmic drug delivery of antiviral agents, and improve patient convenience when prolonged and chronic topical ocular deliveries are intended.

scholarly journals Ocular Drug Delivery: A Special Focus on the Thermosensitive Approach

Nanomaterials ◽  
2019 ◽  
Vol 9 (6) ◽  
pp. 884 ◽  
Author(s):  
Simona Sapino ◽  
Daniela Chirio ◽  
Elena Peira ◽  
Elena Abellán Rubio ◽  
Valentina Brunella ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Body Temperature ◽  
Drug Delivery Systems ◽  
Treatment Options ◽  
In Vitro Models ◽  
Delivery Systems ◽  
Special Focus ◽  
Drug Bioavailability

The bioavailability of ophthalmic therapeutics is reduced because of the presence of physiological barriers whose primary function is to hinder the entry of exogenous agents, therefore also decreasing the bioavailability of locally administered drugs. Consequently, repeated ocular administrations are required. Hence, the development of drug delivery systems that ensure suitable drug concentration for prolonged times in different ocular tissues is certainly of great importance. This objective can be partially achieved using thermosensitive drug delivery systems that, owing to their ability of changing their state in response to temperature variations, from room to body temperature, may increase drug bioavailability. In the case of topical instillation, in situ forming gels increase pre-corneal drug residence time as a consequence of their enhanced adhesion to the corneal surface. Otherwise, in the case of intraocular and periocular, i.e., subconjunctival, retrobulbar, peribulbar administration, among others, they have the undoubted advantage of being easily injectable and, owing to their sudden thickening at body temperature, have the ability to form an in situ drug reservoir. As a result, the frequency of administration can be reduced, also favoring the patient’s adhesion to therapy. In the main section of this review, we discuss some of the most common treatment options for ocular diseases, with a special focus on posterior segment treatments, and summarize the most recent improvement deriving from thermosensitive drug delivery strategies. Aside from this, an additional section describes the most widespread in vitro models employed to evaluate the functionality of novel ophthalmic drug delivery systems.

scholarly journals Recent Advances in the Development of In Situ Gelling Drug Delivery Systems for Non-Parenteral Administration Routes

Pharmaceutics ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 859
Author(s):  
Barbara Vigani ◽  
Silvia Rossi ◽  
Giuseppina Sandri ◽  
Maria Cristina Bonferoni ◽  
Carla M. Caramella ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
In Vitro Release ◽  
Delivery Systems ◽  
Parenteral Administration ◽  
Special Focus ◽  
Ph Change ◽  
Administration Routes ◽  
In Situ Gelling

In situ gelling drug delivery systems have gained enormous attention over the last decade. They are in a sol-state before administration, and they are capable of forming gels in response to different endogenous stimuli, such as temperature increase, pH change and the presence of ions. Such systems can be administered through different routes, to achieve local or systemic drug delivery and can also be successfully used as vehicles for drug-loaded nano- and microparticles. Natural, synthetic and/or semi-synthetic polymers with in situ gelling behavior can be used alone, or in combination, for the preparation of such systems; the association with mucoadhesive polymers is highly desirable in order to further prolong the residence time at the site of action/absorption. In situ gelling systems include also solid polymeric formulations, generally obtained by freeze-drying, which, after contact with biological fluids, undergo a fast hydration with the formation of a gel able to release the drug loaded in a controlled manner. This review provides an overview of the in situ gelling drug delivery systems developed in the last 10 years for non-parenteral administration routes, such as ocular, nasal, buccal, gastrointestinal, vaginal and intravesical ones, with a special focus on formulation composition, polymer gelation mechanism and in vitro release studies.

scholarly journals Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

Pharmaceutics ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 28
Author(s):  
Ognjenka Rahić ◽  
Amina Tucak ◽  
Naida Omerović ◽  
Merima Sirbubalo ◽  
Lamija Hindija ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Contact Lenses ◽  
Delivery Systems ◽  
Medication Therapy ◽  
Ocular Implants ◽  
The One ◽  
Intensive Work ◽  
Novel Drug

Glaucoma is considered to be one of the biggest health problems in the world. It is the main cause of preventable blindness due to its asymptomatic nature in the early stages on the one hand and patients’ non-adherence on the other. There are several approaches in glaucoma treatment, whereby this has to be individually designed for each patient. The first-line treatment is medication therapy. However, taking into account numerous disadvantages of conventional ophthalmic dosage forms, intensive work has been carried out on the development of novel drug delivery systems for glaucoma. This review aims to provide an overview of formulation solutions and strategies in the development of in situ gel systems, nanosystems, ocular inserts, contact lenses, collagen corneal shields, ocular implants, microneedles, and iontophoretic devices. The results of studies confirming the effectiveness of the aforementioned drug delivery systems were also briefly presented.

Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis

2020 ◽  
Vol 26 ◽  
Author(s):  
Ritu Mishra ◽  
Swati Gupta
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Autoimmune Disease ◽  
Drug Delivery Systems ◽  
Clinical Manifestations ◽  
Adaptive Immune Response ◽  
Delivery Systems ◽  
Current Therapy ◽  
Genetic And Environmental Factors ◽  
Novel Drug

Background: Rheumatoid arthritis (RA) is the most common occurring progressive, autoimmune disease, affecting 1% of the population and the ratio of affected women is three times as compared to men in most developing countries. Clinical manifestations of RA are the presence of anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) in blood, tendered joints and soreness of the muscles. Some other factors which may lead to chronic inflammation are genetic and environmental factors as well as adaptive immune response. Several conventional drugs are available for the treatment of RA but have their own drawbacks which can be overcome by the use of novel drug delivery systems. : The objective of the present review is to focus on the molecular pathogenesis of the disease and its current conventional treatment with special reference to the role of novel drug delivery systems encapsulating anti rheumatic drugs and herbal drugs in passive and receptor mediated active targeting against RA. On reviewing the conventional and current therapeutics agains RA, we conclude that, although the current therapy for the treatment of RA is capable enough, yet more advances in the field of targeted drug delivery will sanguinely result in effective and appropriate treatment of this autoimmune disease.

Provesicles as Novel Drug Delivery Systems

2015 ◽  
Vol 16 (4) ◽  
pp. 344-364 ◽  
Author(s):  
Zerrin Bayindir ◽  
Nilufer Yuksel
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Novel Drug

Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review

2017 ◽  
Vol 18 (11) ◽  
Author(s):  
Rohit R. Bhosale ◽  
H. V. Gangadharappa ◽  
Umme Hani ◽  
Riyaz Ali M. Osmani ◽  
Rudra Vaghela ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Novel Drug

Role of novel drug delivery systems in coronavirus disease-2019 (covid-19): time to act now

2020 ◽  
Vol 17 ◽  
Author(s):  
Neeraj Mittal ◽  
Varun Garg ◽  
Sanjay Kumar Bhadada ◽  
O. P. Katare
Keyword(s):  
Drug Delivery ◽  
Targeted Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
World Health ◽  
Ongoing Research ◽  
Standard Drug ◽  
Corona Virus ◽  
Novel Drug

: The corona virus disease 2019 (COVID-19) has found its roots from Wuhan (China). COVID-19 is caused by a novel corona virus SARS-CoV2, previously named as 2019-nCoV. COVID-19 has spread across the globe and declared as pandemic by World health organization (WHO) on 11th March, 2020. Currently, there is no standard drug or vaccine available for the treatment, so repurposing of existing drugs is the only solution. Novel drug delivery systems (NDDS) will be boon for the repurposing of drugs. The role of various NDDS in repurposing of existing drugs for treatment of various viral diseases and their relevance in COVID-19 has discussed in this paper. It focuses on the currently ongoing research in the implementation of NDDS in COVID-19. Moreover it describes the role of NDDS in vaccine development for COVID-19. This paper also emphasizes how NDDS will help to develop the improved delivery systems (dosage forms) of existing therapeutic agents and also explore the new insights to find out the void spaces for a potential targeted delivery. So in these tough times, NDDS and nanotechnology can be a safeguard to humanity.

Improving the Efficacy of Anticancer Drugs via Encapsulation and Acoustic Release

2018 ◽  
Vol 18 (10) ◽  
pp. 857-880 ◽  
Author(s):  
Salma E. Ahmed ◽  
Nahid Awad ◽  
Vinod Paul ◽  
Hesham G. Moussa ◽  
Ghaleb A. Husseini
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Special Focus ◽  
Nano Drug Delivery ◽  
Medical Researchers ◽  
History Of ◽  
Overall Performance ◽  
Enhanced Stability

Conventional chemotherapeutics lack the specificity and controllability, thus may poison healthy cells while attempting to kill cancerous ones. Newly developed nano-drug delivery systems have shown promise in delivering anti-tumor agents with enhanced stability, durability and overall performance; especially when used along with targeting and triggering techniques. This work traces back the history of chemotherapy, addressing the main challenges that have encouraged the medical researchers to seek a sanctuary in nanotechnological-based drug delivery systems that are grafted with appropriate targeting techniques and drug release mechanisms. A special focus will be directed to acoustically triggered liposomes encapsulating doxorubicin.

Recent Advances in the Development of Polymeric Nanocarrier Formulations for the Treatment of Colon Cancer

2019 ◽  
Vol 9 (1) ◽  
pp. 2-14
Author(s):  
Sahil Kumar ◽  
Bandna Sharma ◽  
Kiran Thakur ◽  
Tilak R. Bhardwaj ◽  
Deo N. Prasad ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Colon Cancer ◽  
Hyaluronic Acid ◽  
Targeted Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Near Ir ◽  
Targeted Drug ◽  
Poly Ethylene ◽  
Novel Drug

Background: Many efforts have been explored in the last decade to treat colon cancer but nanoparticulate drug delivery systems are making a vital contribution in the improvement of drug delivery to colon cancer cells. Objective: In this review, we attempt to highlight recent advancements in the development of novel drug delivery systems of nanoparticles for the targeted drug delivery to colon. Polymers like Epithelial Cell Adhesion Molecule (EpCAM) aptamer chitosan, Hyaluronic Acid (HA), Chitosan (CS)– Carboxymethyl Starch (CMS), silsesquioxane capped mesoporous silica, Near IR (NIR) fluorescent Human Serum Albumin (HAS), poly(ethylene glycol)-conjugated hyaluronic acid etc. have been discussed by employing various anticancer drugs like doxorubicin, oxaliplatin, paclitaxel, 5-fluorouracil etc. Conclusion: These novel drug delivery systems have been determined to be more efficacious in terms of stability, sustained and targeted drug delivery, therapeutic efficacy, improved bioavailability and enhanced anticancer activity.

Sign in / Sign up

Export Citation Format

Share Document